The obesity drug helped people trim about two inches more off their waists than Wegovy in the first head-to-head study of the ...

Eli Lilly and Company's stock dropped 11% after CVS's Zepbound exclusion, but analysts see a mispricing opportunity. Click for why LLY growth remains strong.

Although Novo was first to market with Wegovy and its sister ... The company is also studying Zepbound’s impact on illness and death in a trial that’s due to deliver results in 2027.

Eli Lilly & Co.’s obesity drug Zepbound helped people trim about two inches more off their waists than Novo Nordisk A/S’s ...

With the active ingredients in drugs like Ozempic and Zepbound no longer in shortage, access to medicine for millions who had ...

Eli Lilly on Thursday downplayed CVS Health's decision to drop the company's obesity drug Zepbound from some lists of ...

Caremark stood to receive substantial fees for the weight-loss drugs even without excluding Zepbound. Novo Nordisk and Eli Lilly have a duopoly in the booming market for weight-loss drugs ...